Lexaria Bioscience Corp.LEXXEarnings & Financial Report
Nasdaq
NextApr 14, 2026
LEXX Q1 2026 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-1.6M
Net Profit
$-1.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.07
Lexaria Bioscience Corp. Q1 2026 Financial Summary
Lexaria Bioscience Corp. reported revenue of $0 for Q1 2026, with a net profit of $-1.6M (N/A margin). Cost of goods sold was $0, operating expenses totaled $1.6M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-1.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 2026 |
Lexaria Bioscience Corp. Annual Revenue by Year
Lexaria Bioscience Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $705.9K).
| Year | Annual Revenue |
|---|---|
| 2025 | $705.9K |
| 2024 | $464.3K |
| 2023 | $226.2K |
| 2022 | $255.4K |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145000 | $84000 | $84000 | $183923 | $174000 | $174000 | $174000 | $0 |
| YoY Growth | 314.1% | -9.8% | 2546.8% | 21.6% | 20.0% | 107.1% | 107.1% | N/A |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $6.4M | $10.0M | $8.9M | $9.8M | $8.7M | $6.7M | $4.2M | $6.1M |
| Liabilities | $204203 | $271375 | $1.2M | $399718 | $1.9M | $1.6M | $1.6M | $1.5M |
| Equity | $6.5M | $10.1M | $8.0M | $9.8M | $7.1M | $5.6M | $3.0M | $4.9M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-619614 | $-1.3M | $-1.9M | $-2.7M | $-1.5M | $-3.6M | $-2.6M | $-984098 |